ERCC1 and BRAC1 mRNA Expression Levels in the Primary Tumor Could Predict the Effectiveness of the Second-Line Cisplatin-Based Chemotherapy in Pretreated Patients with Metastatic Non-small Cell Lung Cancer-Reference-Cited by-同舟云学术

ERCC1 and BRAC1 mRNA Expression Levels in the Primary Tumor Could Predict the Effectiveness of the Second-Line Cisplatin-Based Chemotherapy in Pretreated Patients with Metastatic Non-small Cell Lung Cancer

Published:2012-04 Issue:4 Volume:7 Page:663-671
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Papadaki Chara,Sfakianaki Maria,Ioannidis Georgios,Lagoudaki Eleni,Trypaki Maria,Tryfonidis Kostas,Mavroudis Dimitris,Stathopoulos Efstathios,Georgoulias Vassilis,Souglakos John

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference45 articles.

1. Cancer statistics, 2009;Jemal;CA Cancer J Clin,2009

2. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer;Scagliotti;J Clin Oncol,2008

3. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer;Schiller;N Engl J Med,2002

4. Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II study;Douillard;Br J Cancer,2001

5. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial;Georgoulias;Lancet,2001

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study;BMC Cancer;2023-03-02

2. Epigenetics of cisplatin resistance;Epigenetic Cancer Therapy;2023

3. Personalisierter Decision Support für Krebsbehandlung;Wissensbasierte KI-Anwendungen;2023

4. Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: A real- world study;2022-11-30

5. The Prognostic and Therapeutic Potential of DNA Damage Repair Pathway Alterations and Homologous Recombination Deficiency in Lung Cancer;Cancers;2022-10-28